If you have diabetes, taking steps to manage it can help prevent related health issues, including MASH. Here’s what to know ...

Metabolic dysfunction-associated steatohepatitis (MASH) is often referred to as a “silent disease,” as it typically shows no signs of symptoms in early stages. But it can come with certain ...

In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...

These organizations can help you educate yourself, spread awareness, and connect with the MASH community to help you better ...

By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Obesity and diabetes are the leading causes of metabolic dysfunction-associated steatohepatitis (MASH), which is the most ...

Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...